[{"id":"37756612-b346-458d-bbf9-9e3a38cba018","acronym":"","url":"https://clinicaltrials.gov/study/NCT05935098","created_at":"2023-07-07T14:09:28.288Z","updated_at":"2024-07-02T16:34:59.858Z","phase":"Phase 1","brief_title":"A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05935098","lead_sponsor":"BeiGene","biomarkers":" CCR8","pipe":" | ","alterations":" PD-L1 expression • CCR8 expression","tags":["CCR8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CCR8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • BGB-A3055"],"overall_status":"Recruiting","enrollment":" Enrollment 318","initiation":"Initiation: 08/21/2023","start_date":" 08/21/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-31"}]